Brenda Martone, a nurse practitioner at Northwestern Medicine in Chicago Illinois and Dr Alicia Morgans, Genitourinary Medical Oncologist at the Dana-Farber Cancer Institute in the United States discuss ‘Shared decision-making in nmCRPC: Treatment considerations to maintain quality of life’ in this GU CONNECT podcast. In this podcast, the experts discuss how patients are more likely to be able to adhere to a treatment plan if they understand their choices and the implications of each treatment. They discuss how nmCRPC patients are relatively asymptomatic and the importance of understanding the patients’ goals of treatment and how these may differ from a physician’s perspective. Alicia reviews the efficacy and safety data from the key trials for nmCRPC, the SPARTAN trial with apalutamide, the PROSPER trial with enzalutamide and the ARAMIS trial with darolutamide. Brenda discusses ways to manage adverse events for the nmCRPC patients in order to keep them on treatment whilst still maintaining a good quality of life and Alicia explains how she goes about determining the right treatment for the right patient whilst considering comorbidities and drug to drug interactions.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related